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Key Points 
 
• IDH2 is a new synthetic lethal target to proteasome inhibitors (PIs), efficacious in 
several hematological malignancies. 
• Inhibition of NAMPT/SIRT3/IDH2 pathway could enhance the therapeutic efficacy 
and overcome resistance to PIs.  
 
ABSTRACT 
 
Proteasome inhibitors (PIs) are extensively used for the therapy of multiple myeloma (MM) 
and mantle-cell lymphoma (MCL). However, patients continuously relapse or are 
intrinsically resistant to this class of drugs. Here, to identify targets that synergize with PIs, 
we carried out a functional screening in MM cell lines using a short hairpin RNA library 
against cancer driver genes. Isocitrate dehydrogenase 2 (IDH2) was identified as a top 
candidate, showing a synthetic lethal activity with the PI carfilzomib (CFZ). Combinations 
of FDA approved PIs with a pharmacological IDH2 inhibitor (AGI-6780) triggered 
synergistic cytotoxicity in MM, MCL, and Burkitt’s lymphoma (BL) cell lines. CFZ/AGI-6780 
treatment increased death of primary CD138+ cells from MM patients and exhibited a 
favorable cytotoxicity profile towards peripheral blood mononuclear cells and bone 
marrow-derived stromal cells. Mechanistically, CFZ/AGI-6780 combination significantly 
decreased tricarboxylic acid (TCA) cycle activity and ATP levels, as a consequence of 
enhanced IDH2 enzymatic inhibition. Specifically, CFZ treatment reduced the expression 
of nicotinamide phosphoribosyltransferase (NAMPT), thus limiting IDH2 activation through 
the NAD+-dependent deacetylase SIRT3. Consistently, combination of CFZ with either 
NAMPT or SIRT3 inhibitors impaired IDH2 activity and increased MM cell death. Finally, 
inducible IDH2 knockdown enhanced the therapeutic efficacy of CFZ in a subcutaneous 
xenograft model of MM, resulting in inhibition of tumor progression and extended survival. 
Taken together, these findings indicate that NAMPT/SIRT3/IDH2 pathway inhibition 
enhances the therapeutic efficacy of PIs, thus providing compelling evidence for 
treatments with lower and less toxic doses and broadening the application of PIs to other 
malignancies. 
 
  
For personal use only.on November 29, 2018. by guest  www.bloodjournal.orgFrom 
  
 
3 
 
INTRODUCTION 
 
The ubiquitin-proteasome pathway plays a crucial role in protein processing and 
degradation, regulating critical cellular functions including cell-cycle control, transcriptional 
regulation, cellular stress responses, and antigen presentation.1 It is well established that 
proteasome inhibition results in the disruption of normal homeostatic mechanisms, and 
that malignant cells are more susceptible to the cytotoxic effects of proteasome inhibition 
than normal cells, most likely as a consequence of their increased requirement for protein 
synthesis and their higher levels of proteasome activity.2 A number of processes have 
been reported to contribute to the antitumoral effects of proteasome inhibitors (PIs), 
including inhibition of the NF-κB pathway,3 altered cell cycle control and apoptosis 
mechanisms,4,5 endoplasmic reticulum stress, suppression of cell adhesion signaling, 
inhibition of angiogenesis and DNA repair.2 The prevalent sensitivity of transformed cells 
to PIs and the successful design of clinical protocols, have led to the regulatory approval of 
PIs to treat multiple myeloma (MM) and mantle-cell lymphoma (MCL) patients.6–10 To date, 
three PIs are routinely used in clinical settings (bortezomib, carfilzomib, and ixazomib), 
and additional PIs are under investigation.11 The pleiotropic consequences of proteasome 
inhibition result in synergistic or additive activity with other therapeutic protocols including 
autologous stem cell transplantation (ASCT), glucocorticoids, alkylating agents and 
anthracyclines, immunomodulatory drugs, histone deacetylase inhibitors, and monoclonal 
antibodies.10,12 Despite these enormous advances, relapses and disease progressions are 
common among MM patients, suggesting a prominent role for either innate or 
acquired drug-resistance.13,14 Moreover, although the toxicity of PIs is quite well controlled 
in clinical settings, they display distinct adverse profiles, imposing limits to their doses.15 In 
addition, responses to PIs in other hematological malignancies have been 
contradictory.6,16,17 Similarly, promising preclinical data obtained with PIs in models of solid 
tumors have not been confirmed in the clinic,15 probably as a consequence of impaired 
drug distribution, requiring higher dosages, not applicable for the toxic effects. Therefore, 
the design of a new generation of ubiquitin-proteasome pathway inhibitors and the 
identification of novel combination strategies is essential to overcome resistance and 
broaden the applicability of this class of drugs to other hematological malignancies, and 
possibly to solid tumors.  
Here, to identify druggable targets which inhibition sensitize MM cells to PIs, we performed 
a short hairpin RNA functional screening targeting 152 cancer driver genes. Isocitrate 
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dehydrogenase 2 (IDH2) silencing revealed synthetic lethal activity with carfilzomib (CFZ). 
Combinations of the pharmacological IDH2 inhibitor AGI-6780 with PIs triggered 
synergistic cytotoxicity in MM, MCL, and Burkitt’s lymphoma (BL) cell lines, as well as in 
primary CD138+ cells from MM patients. Importantly, inducible IDH2 knock-down 
enhanced the therapeutic efficacy of CFZ in a subcutaneous xenograft model of MM. Our 
findings indicate that the NAMPT/SIRT3/IDH2 pathway is a major determinant of PIs 
responsiveness in hematological malignancies, thus providing proof of concept for new 
combination strategies to enhance sensitivity and overcome resistance to PIs. 
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MATERIALS AND METHODS 
 
Detailed experimental procedures for cell culture conditions, shRNA screening, plasmid 
constructs, virus production, in vitro transduction, generation of inducible cell lines, 
purification of total RNA and Reverse Transcription-quantitative Polymerase Chain 
Reaction (RT-qPCR), DNA sequencing, western blotting, Gene Expression Profiling, 
analysis of apoptosis and cell cycle, analysis of reactive oxygen species (ROS) production, 
mitochondria isolation, and NF-κB activity are included in supplemental Material and 
Methods, available on the Blood web site. 
 
Tricarboxylic acid (TCA) cycle measurement 
 
The glucose flux through TCA cycle was measured by radiolabeling cells with 2 μCi/mL [6-
14C]-glucose (55 mCi/mmol; PerkinElmer, Waltham, Massachusetts, USA). Cell 
suspensions were incubated for 1 hour in a closed experimental system to trap the 14CO2 
developed from [14C]-glucose, and the reaction was stopped by injecting 0.5 mL of 0.8 N 
HClO4. The amount of glucose transformed into CO2 through the TCA cycle was 
calculated as described,18 and expressed as pmoles CO2/h/mg cell proteins. 
 
IDH enzymatic activity 
 
Isocitrate Dehydrogenase Activity was measured using the IDH assay kit (Sigma-Aldrich, 
St. Louis, Missouri, USA), according to the manufacturer’s protocol. IDH activity was 
determined using isocitrate as a substrate of the reaction, which results in a colorimetric 
(450 nm) product proportional to the enzymatic activity present. One unit of IDH is the 
amount of enzyme that generates 1.0 μmole of NADH or NADP per minute at pH 8.0 at 
37°C. To evaluate IDH2 and IDH1 activities, mitochondrial or cytoplasmic extracts were 
respectively used. 
 
Measurement of complex I–III activity 
 
Mitochondria were extracted as described in supplemental Material and Methods. The 
electron flux from complex I to complex III was measured in 50 μL non-sonicated 
mitochondrial extracts, resuspended in 120 μL buffer A (5 mM KH2PO4, 5 mM MgCl2, 5% 
For personal use only.on November 29, 2018. by guest  www.bloodjournal.orgFrom 
  
 
6 
 
w/v BSA) in a 96 well plate. Then, 100 μL buffer B (25% w/v saponin, 50 mM KH2PO4, 5 
mM MgCl2, 5% w/v BSA, 0.12 mM cytochrome c-oxidized form, 0.2 mM NaN3) was added 
for 5 min at room temperature. The reaction was started with 0.15 mM NADH and was 
followed for 6 min, reading the absorbance at 550 nm by a Lambda 3 spectrophotometer 
(PerkinElmer). Results were expressed as nmoles cytochrome c reduced/min/mg 
mitochondrial proteins.19 
 
ATP measurement 
 
The amount of ATP was measured in 50μL mitochondrial extracts with the ATPlite assay 
(PerkinElmer), using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments, 
Winooski, Vermont, USA). ATP was quantified as arbitrary light units; data were converted 
into nmoles/mg mitochondrial proteins, using a calibration curve previously set. 
 
Xenograft models 
 
KMS-27-TK-IDH2-A4 cells (5 x 105) suspended in phosphate-buffered saline (PBS)–50% 
Matrigel (BD Biosciences, San Jose, California, USA) were injected into the left and right 
flanks of NOD/SCID/IL2Rγ−/− (NSG) mice, previously anesthetized intramuscularly with 
xylazine and tiletamine/zolazepam. Tumor growth was monitored over time by determining 
the volume of tumor masses. Mice with tumor masses of 0.5 cm diameter (∼3 weeks after 
the injection) were randomized and treated for 3 weeks with doxycycline by oral 
administration (0.1 mg/mL biweekly), CFZ i.v. (4 mg/kg biweekly), or the combination with 
the same dosing regimen used for the individual agents. Doxycycline was administrated in 
a 0.5% sucrose solution in light-proof bottles, for 48h. CFZ was dissolved in 3% DMSO, 
10% Captisol (CYDEX Pharmaceuticals Inc., Lenexa Kansas, USA), 10 mM sodium citrate 
pH 3.5, and administrated after doxycycline removal. The control group received the 
carriers alone at the same schedule as the combination group. Mice were euthanized in a 
carbon dioxide chamber, after the tumor masses reached a volume of approximately 1 500 
mm3, or at early signs of distress. Tumor volume was calculated using the ellipsoid formula 
4/3 x π x ½ x (length x width x depth). Animals were housed in the animal facility of the 
Molecular Biotechnology Center (Torino, Italy), in accordance with guidelines approved by 
the local Ethical Animal Committee. Experimental approval was obtained from the Italian 
Ministry of Health.  
For personal use only.on November 29, 2018. by guest  www.bloodjournal.orgFrom 
  
 
7 
 
 
Statistical analysis 
 
Statistical analyses were performed with GraphPad Prism 5.01 (GraphPad Software Inc.). 
Statistical significance of differences observed (in both in vitro and in vivo experiments) 
was determined by Student t test; differences were considered significant when P value 
was <.05 (*), <.01 (**), or <.001 (***). Survival curves were estimated with the Kaplan-
Meier method. The log-rank test was used for statistical analysis. 
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RESULTS 
 
shRNA screening in multiple myeloma cell lines identifies IDH2 gene as synthetic 
lethal to the proteasome inhibitor carfilzomib 
 
To identify druggable targets that synergize with PIs, we generated two MM cell lines 
(KMM-1PIR and U266PIR) cross-resistant to the PIs bortezomib (BTZ) and carfilzomib (CFZ) 
(supplemental Figure S1). A functional screening using a short hairpin RNA library 
targeting 152 cancer driver genes, highly representative of all signaling pathways, was 
carried out in the KMM-1PIR cell line treated with sub-lethal concentrations of CFZ (Figure 
1A-B; supplemental Table S1-6). The primary screening was validated in the U266PIR cell 
line, by targeting the top 24 genes (supplemental Table S7). Analysis of the correlation 
between gene silencing efficacy and growth inhibition in presence of CFZ led to the 
identification of 3 synthetic lethal target genes (Figure 1C). Further studies were focused 
on isocitrate dehydrogenase 2 (IDH2), a NADP+ dependent mitochondrial enzyme, that 
catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate in tricarboxylic acid 
(TCA) cycle. To validate screening results, two shRNA sequences (A4 and A6) directed 
against human IDH2 were individually transduced into KMM-1PIR and U266PIR cells 
(supplemental Figure S2). IDH2 knockdown did not affect viability of KMM-1PIR and 
U266PIR cells. In contrast, IDH2 depletion was dramatically cytotoxic in cells treated with a 
sub-lethal dose of CFZ (Figure 1D-E). We excluded that IDH2 mutations or its aberrant 
expression were associated to PIs resistance in MM cells (supplemental Figure S3). These 
findings prompted us to verify whether IDH2 knockdown could synergize with CFZ also in 
PI-sensitive cell lines. Accordingly, IDH2 silencing considerably enhanced sensitivity to 
CFZ in parental KMM-1 and U266 cell lines (Figure 1F-G). Taken together these data 
established that IDH2 knockdown is synthetic lethal to CFZ treatment in both PI resistant 
and sensitive MM cell lines. 
 
Pharmacological inhibition of IDH2 enhances sensitivity to CFZ in MM cell lines 
 
To define whether pharmacological inhibition of IDH2 recapitulates the synthetic lethal 
phenotype, CFZ treatment was associated to AGI-6780, an allosteric inhibitor of mutant 
IDH2, known to reduce the activity of wild type IDH2, although less potently.20,21 We first 
demonstrated that AGI-6780 (5 μM) selectively impaired IDH2 enzymatic activity in MM 
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cells (supplemental Figure S4A-D). Next, the PIs resistant MM cell lines KMM-1PIR and 
U266PIR were treated with either CFZ, AGI-6780, or the combination of the two drugs. 
Combinatorial treatments significantly increased cell death, compared to single drugs 
(Figure 2A-B), confirming data obtained by IDH2 knockdown. This combination was 
effective also in MM cells resistant to very high concentrations of PIs (Figure 2C; 
supplemental Figure S5). To prove that the combined cytotoxicity of AGI-6780 and CFZ is 
not restricted to PI resistant cells, eight MM cell lines with different degrees of PI sensitivity 
were treated with a single dose of CFZ in combination or not with AGI-6780, refreshed 
every 48 hours. Enhanced sensitivity to the combination treatment in comparison with 
either agent alone was observed in all MM cell lines (Figure 2D; supplemental Figure S6A-
B). In contrast, the chronic myelogenous leukemia cell line K-562 was unresponsive to 
both drugs and to their combination (Figure 2D). Increased sensitivity to CFZ was 
confirmed in two MM cell lines (KMS-27 and U266) by regimens with lower doses of CFZ 
administered every 48 hours in combination with AGI-6780 (supplemental Figure S6C-D). 
Considering that hypoxic bone marrow microenvironment favors MM progression and drug 
resistance, we tested if this environment could affect the response to PIs and AGI-6780.22–
24
 We confirmed that the combination of the two drugs increased MM cell death, also in 
presence of cells cultured with 1% oxygen concentration (supplemental Figure S7). To 
elucidate mechanisms of synthetic lethality, cell cycle and apoptotic markers were 
analyzed. CFZ/AGI-6780 combination was associated with an increase of G0/G1 phase 
(supplemental Figure S8), down-modulation of cyclins, up-regulation of cyclin-dependent 
kinase inhibitors, proteolytic cleavage of the caspases substrate PARP-1, and activation of 
effector caspases 3, 7, and 9 (Figure 2E). To reduce the confounding effects of cell death 
induction, western blotting and cell cycle analysis were performed 24 hours post-
treatment, when cells displayed comparable levels of viability (Figure 2F-G). To further 
define the molecular mechanisms involved and/or regulated by the synergistic activity of 
CFZ/AGI-6780, gene expression profiles were analyzed 6 and 12 hours after single or 
combination treatments, and compared with untreated control samples. Supervised 
analysis identified 115 genes differentially regulated by CFZ, while AGI-6780 treatment 
had negligible transcriptional effects. Remarkably, 261 genes were differentially expressed 
after combined treatment, and nearly all genes modulated by CFZ (106/115) were 
concordantly modified to a higher degree by CFZ/AGI-6780 treatment (supplemental 
Figure S9A). Pathway analyses confirmed that the classical targets of PIs such as 
unfolded protein response (UPR), NF-κB, cell cycle, and apoptosis, were affected in 
For personal use only.on November 29, 2018. by guest  www.bloodjournal.orgFrom 
  
 
10 
 
response to CFZ alone and these effects were enhanced by the combination with AGI-
6780 (supplemental Figure S9B). Collectively, these findings indicate that the CFZ/AGI-
6780 regimen is effective against PI-resistant and PI-sensitive MM cells and elicits 
significant changes converging in cell cycle and apoptotic pathways. 
 
IDH2 inhibition synergizes with first- and second-generation PIs in B-cell 
hematological malignancies 
 
To expand the clinical relevance of our observations and demonstrate that IDH2 inhibition 
specifically synergize with PIs, we first demonstrated that MM cells treated with AGI-6780 
displayed enhanced response to the FDA approved PIs bortezomib (BTZ) and ixazomib 
(IXA) (supplemental Figure S10A-B). Since PIs have been approved also for the treatment 
of MCL patients and their anticancer effects have been obtained in different types of 
hematological malignancies,6,25 we tested whether IDH2 inhibition could synergize with PIs 
in B-cell non-Hodgkin lymphoma models. Remarkably, a dramatic increase of cell death 
was observed in all MCL and BL cell lines treated with CFZ/AGI-6780 combinations 
(Figure 3). We then asked whether increased IDH2 activity could impair the cytotoxicity of 
PIs. As it is known that SIRT3 protein de-acetylates IDH2 and enhances its activity under 
glucose deprivation,26,27 we cultured KMM-1 cells in absence of glucose for 7 days and 
measured IDH1, IDH2, and IDH3 enzymatic activities. As expected, a stable induction of 
IDH2 activity was observed after glucose restriction (supplemental Figure S10C). Next, we 
evaluated whether IDH2 activation was able to rescue MM cells from the effect of 
CFZ/AGI-6780 combination. KMM-1 cells were conditioned by glucose deprivation for 24 
hours and subsequently treated with CFZ, AGI-6780, or with the two agents. Significantly, 
glucose restriction increased the viability of CFZ- and CFZ/AGI-6780-treated cells, as 
compared to not starved cells (supplemental Figure S10D). Moreover, we performed a 
canonical rescue experiment overexpressing IDH2 and/or SIRT3 in KMM-1PIR cells 
(supplemental Figure S10E). We observed that only the combined overexpression of the 
two genes was able to enhance IDH2 activity (supplemental Figure S10F). Concordantly, 
cells with hyperactivation of IDH2 treated with CFZ and AGI-6780 partially decrease cell 
death, compared to the cells with a basal IDH2 activity (supplemental Figure S10G). Taken 
together these results suggest that IDH2 activity antagonizes the therapeutic efficacy of 
first- and second-generation PIs and that pharmacological IDH2 inhibition is a suitable 
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strategy to enhance the therapeutic efficacy of PIs in MM and other B-cell hematological 
malignancies. 
 
CFZ/AGI-6780 combinatorial treatment decreases TCA cycle activity and 
mitochondrial ATP production through the NAMPT/SIRT3/IDH2 pathway 
 
To define the molecular mechanisms responsible for the synergy between PIs and IDH2 
inhibition, we considered that targeting IDH2 activity could lead to a decrease of NADPH 
production, resulting in higher reactive oxygen species (ROS) levels.28 Taking into account 
that oxidative stress has been identified as an important mechanism of PI cytotoxicity in 
myeloma and non-myeloma cells,29,30 we hypothesized that CFZ/AGI-6780 combination 
could exacerbate ROS levels, thus leading to increased cell death. However, only a slight 
increase in mitochondrial ROS concentration was observed in MM cells treated with 
CFZ/AGI-6780 combination (supplemental Figure S11). Next, we evaluated if IDH2 
inhibition could impair tricarboxylic acid (TCA) cycle activity.28 Notably, we observed that 
CFZ/AGI-6780 combination more drastically decreased IDH2 and TCA cycle activities, 
despite CFZ treatment was ineffective (Figure 4A-D). In this setting, IDH2 inhibition was 
associated to a proportional increase in IDH1 and IDH3 activities (supplemental Figure 
S12). In addition, electron transport chain (ETC) flux and mitochondrial ATP synthesis 
were accordingly down-regulated in MM cells treated with the combination of the two drugs 
(Figure 4E-F). Subsequently, we examined the biochemical mechanisms whereby CFZ 
treatment could synergize with AGI-6780 to further decrease IDH2 activity. It is recognized 
that PIs inhibit NF-κB10,31 and that expression of nicotinamide phosphoribosyltransferase 
(NAMPT), a rate-limiting enzyme in the NAD+ synthesis and sirtuins activation,32 is 
transcriptionally modulated by NF-κB.33–35 Therefore, we reasoned that PIs could affect 
IDH2 activation through the NAMPT/NAD+/SIRT3 pathway (Figure 5A). Consistent with 
this hypothesis, we demonstrated that CFZ treatment significantly reduced NF-κB activity 
in KMS-27 cells (Figure 5B). Accordingly, NAMPT expression levels were significantly 
down-regulated by CFZ treatment (Figure 5C). To confirm the involvement of the 
NAMPT/NAD+/SIRT3 pathway, we associated CFZ with several NAMPT inhibitors (FK866, 
GMX-1778, and Nampt-IN-1). As expected, combination of CFZ with NAMPT inhibitors 
induced synergistic down-regulation of IDH2 and TCA activity (Figure 5D; supplemental 
Figure S13A), followed by MM cell death, confirming the synthetic lethality previously 
reported by Cagnetta, et al with BTZ and FK866 (Figure 5E; supplemental Figure S13B-
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C).36 Importantly, these results were phenocopied by associating CFZ treatment to SIRT3 
inhibition, both using specific drugs (AGK7 and TYP-3) (Figure 5F-G; supplemental Figure 
S13D-E) and shRNAs targeting SIRT3 (supplemental Figure S13F-G).37 
Taken together these data demonstrate that CFZ/AGI-6780 combination significantly 
decreases TCA cycle activity, as a consequence of enhanced IDH2 enzymatic inhibition. 
Specifically, CFZ treatment reduces NAMPT expression and thus limits IDH2 activation 
through the NAD+-dependent deacetylase SIRT3. 
 
Targeting IDH2 and proteasome activities triggers synergistic inhibition of human 
MM cells growth ex-vivo and in vivo with low toxicity to normal human cells 
  
To evaluate whether IDH2 inhibition potentiates CFZ effect in primary cells from MM 
patients, buffy coats derived from bone marrow aspirates of 9 MM patients were cultured 
on a layer of HS-5, a bone marrow stromal cell line. Ex-vivo co-cultures were treated with 
CFZ/AGI-6780 combination or with the single drugs for 96 hours. Combination treatment 
significantly decreased viability of CD138+ cells (Figure 6A). Next, we demonstrated that 
CFZ/AGI-6780 treatment exhibited a favorable cytotoxicity profile towards peripheral blood 
mononuclear cells and bone marrow-derived stromal cells, compared to KMS-27 (Figure 
6B-C). Taking into account that AGI-6780 is not suitable for in vivo studies,38 and that 
enasidenib (AG-221), the mutant IDH2 inhibitor used in the clinic, does not affect the 
activity of wild-type IDH2,21 we exploited a conditional RNAi method to knock-down IDH2 
expression.39,40 To provide an in vivo proof of principle that IDH2 inhibition could increase 
the therapeutic efficacy of PIs in MM, we expressed an IDH2-shRNA (IDH2-A4) in KMS-27 
cell line under the control of the doxycycline-regulated transcriptional repressor tTR-KRAB 
(TK). We next studied the growth patterns of KMS-27-TK-IDH2-A4 cells injected 
subcutaneously into the flanks of NOD/SCID/IL2Rγ−/− (NSG) mice. Mice with masses of 
0.5 cm in diameter were treated with doxycycline (DOXY; 0.1 mg/mL biweekly), CFZ (4 
mg/kg biweekly), or control diluents. Administration of either agent had a substantial effect 
on tumor growth, as compared to control mice (P<.0001). Importantly, when IDH2 
silencing was combined to CFZ, there was a further significant reduction in tumor growth in 
relation to single treatments (CFZ vs CFZ/DOXY P=.0244; DOXY vs CFZ/DOXY P=.0238; 
Figure 6D). The median overall survival of mice treated with CFZ associated to IDH2 
silencing was significantly longer than vehicle-treated mice (26 vs 49 days; P=.0001), or 
mice treated with either drug alone (35 days for CFZ and 38 days for DOXY) (Figure 6E). 
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Together, these findings indicate that the anti-tumor activity of CFZ/AGI-6780 combination 
extends to primary explants from MM patients with a favorable therapeutic index and 
provide an in vivo proof of principle that IDH2 inhibition could increase the therapeutic 
efficacy of PIs. 
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DISCUSSION 
 
Even though PIs have led to substantial outcome improvements in MM and MCL patients, 
development of novel combination strategies is needed to overcome resistance and 
broaden the applicability of this class of drugs to other malignancies. 
The present study identified IDH2 as a new synthetic lethal target to PIs, efficacious in 
several hematological malignancies including MM, MCL, and BL. We showed that the 
combined targeting of IDH2 and proteasome triggers synergistic inhibition of human MM 
ex-vivo and in vivo, with low toxicity to normal human cells. We demonstrated that the 
NAMPT/SIRT3/IDH2 pathway is a major determinant of PIs responsiveness, thus 
providing a proof of concept for new combination strategies to enhance sensitivity and 
broaden the application of PIs to other malignancies.  
IDH2 is a mitochondrial enzyme that catalyzes the reversible oxidative decarboxylation of 
isocitrate to alpha-ketoglutarate, with concomitant reduction of NADP+ to NADPH. Hotspot 
mutations in IDH2 gene have been identified in acute myeloid leukemias (AML),41,42 
angioimmunoblastic T-cell lymphomas (AITL),43 and several other malignancies.42,44–47 
IDH2 mutations cause a loss of IDH2 activity and an enzymatic gain of function that 
catalyzes the conversion of alpha-ketoglutarate to (R)-hydroxyglutarate (2-HG), with 
consequences on metabolism, epigenetic state, and cellular differentiation.48,49 The 
appreciation of the role of IDH2 mutations in oncogenesis and their early occurrence 
prompted to the approval of the IDH2-mutant inhibitor enasidenib (AG-221) for the 
treatment of refractory/relapsed IDH2-mutated AML patients. 
In contrast, the potential role of wild-type IDH2 and its clinical relevance in cancers has 
been poorly investigated. It is thought that the impact of IDH2 expression on neoplastic 
progression and drug resistance differs with respect to the site of origin and histological 
type.50–55 Our study suggests the hypothesis that inhibition of wild-type IDH2 may have 
therapeutic potentials, regardless of IDH2 expression levels. Concordantly, we excluded 
that the IDH2 mutational status or its aberrant expression was associated to PIs 
responsiveness in MM cells. Analysis of gene expression profiling datasets did not detect 
significant changes of IDH2 expression in the evolution of MM disease (data not shown). 
However, evaluation of IDH2 enzymatic activity could be more appropriate to further 
dissect the relevance of IDH2 in tumor development and maintenance, as well as a 
possible prognostic factor. 
We demonstrated that genetic and pharmacological inhibition of IDH2 synergizes with 
first- and second-generation PIs by enhancing tumor cells death. In contrast, induction of 
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IDH2 enzymatic activity through glucose starvation impairs the therapeutic efficacy of PIs, 
confirming that pharmacological IDH2 inhibition is a suitable strategy to enhance PIs 
effects. 
Mechanistically, we observed that CFZ significantly down-regulates NAMPT expression 
levels, most likely through the inhibition of NF-κB.33–35 NAMPT is a key NAD pathway 
intermediate that catalyzes the transfer of a phosphoribosyl group from 5-phosphoribosyl-
1-pyrophosphate (PRPP) to nicotinamide, forming nicotinamide mononucleotide (NMN). It 
has been previously shown that NAMPT inhibition is synthetic lethal to BTZ in MM.36 Here, 
we demonstrated that combination of CFZ with either NAMPT or SIRT3 inhibitors induces 
synergistic down-regulation of IDH2 activity through the impairment of 
NAMPT/SIRT3/IDH2 pathway. The strong impairment of this pathway drastically 
decreases IDH2 and TCA cycle activities, leading to ETC flux and mitochondrial ATP 
synthesis down-regulation. However, we could not exclude that additional mechanisms 
may contribute to the anti-tumoral effects of CFZ/AGI-6780 combination. 
We showed that the combined targeting of IDH2 and proteasome activities triggers 
synergistic inhibition of primary human MM cells.  Importantly, CFZ/AGI-6780 combination 
exhibits a favorable cytotoxicity profile toward peripheral blood mononuclear cells and 
bone marrow–derived stromal cells. Considering the efficacy of CFZ/AGI-6780 also in PI-
resistant cell lines, we speculate that this combination could be successful also in relapsed 
and refractory MM patients. To answer this question, further studies in cohort of patients 
stratified for their PI response are required. We extended the clinical relevance of our 
observations proving that IDH2 inhibition synergizes with PIs in several B-cell non-Hodgkin 
lymphoma cell lines including MM, MCL, BL, and diffuse large B-cell lymphomas (data not 
shown). Our preclinical studies therefore provide the rationale for development of novel 
IDH2 inhibitors directed against wild type IDH2. These observations are in line with recent 
studies highlighting the importance of wild-type IDH1 as therapeutic potential.56–58 A further 
interesting expansion to the present work would be to investigate whether IDH2 synthetic 
lethal interaction to PIs could also take place in cancer patients with mutant IDH2, such as 
AML, AITL, and other malignancies. 
Finally, we provided an in vivo proof of principle that IDH2 inhibition enhances the 
therapeutic efficacy of CFZ in a subcutaneous xenograft model of MM, resulting in 
inhibition of tumor progression and extended survival. Owing to the lack of wt-IDH2 
inhibitors suitable for an in vivo use, we exploited a conditional shRNA system to knock-
down IDH2. In contrast to in vitro data, in vivo IDH2 inhibition has a more substantial effect 
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on tumor growth, probably as a consequence of higher gene silencing obtained with the 
inducible shRNA.  
In conclusion, the present study identified IDH2 as a new synthetic lethal target to PIs, 
efficacious in several hematological malignancies. We demonstrated that the 
NAMPT/SIRT3/IDH2 pathway is a major determinant of PIs responsiveness, thus 
providing a proof of concept for new combination strategies to enhance sensitivity and 
broaden the application of PIs to other malignancies.  
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FIGURE LEGENDS 
 
Figure 1. shRNA screening in multiple myeloma cell lines identifies IDH2 gene as 
synthetic lethal to the proteasome inhibitor carfilzomib. (A) Experimental design of the 
shRNA screen to identify genes conferring sensitivity to carfilzomib (CFZ) in multiple 
myeloma cells. KMM-1PIR cells were infected with 684 shRNAs targeting 152 cancer driver 
genes (day -3) and incubated in presence or absence of puromycin (day -2). KMM-1PIR 
cells were then splitted and treated with 2.5 nM CFZ or with control diluent (DMSO) (day 
0). Growth rate was calculated at day 3 and 7 post-treatment (supplemental Table S5), 
and positive hits selected according to the Z-score. Top 24 selected genes were validated 
in a secondary screening performed in U266PIR cells. (B) Representation of the Z-score (y-
axis) for every shRNA (x-axis) calculated on growth rate reduction for each shRNA. Red 
box highlights candidates with Z-score below -0.8 (day 7) (supplemental Table S6). (C) 
Correlation between percentage of gene silencing and percentage of growth inhibition in 
presence of CFZ for top 3 candidate genes (IDH2, KDM1A, and SOX2) in U266 PIR cells. 
(D) KMM-1PIR, (E) U266PIR, (F) KMM-1, and (G) U266 cell lines were transduced with the 
empty vector or shRNAs targeting IDH2 (shIDH2_A4, shIDH2_A6) and treated with CFZ 
(KMM-1PIR and U266PIR: 5 nM; KMM-1 and U266: 2.5 nM) or DMSO every 48h. Cell 
viability was measured by TMRM staining-flow cytometry 96 hours post-treatment (hpt) for 
KMM-1PIR and U266PIR, 48 hours post-treatment (hpt) for KMM-1 and U266. Data are the 
means ± s.d. of three independent experiments (*P<.05; **P<.01).  
 
Figure 2. Pharmacological inhibition of IDH2 enhances sensitivity to CFZ in MM cell 
lines. (A) KMM-1PIR and (B) U266PIR cells were treated with 2.5 nM CFZ in combination or 
not with 10 μM AGI-6780. Cell viability was measured by TMRM staining-flow cytometry 96 
hours post-treatment. Data are the means ± s.d. of four independent experiments. (C) 
U266PIR50 cells were treated with 75 nM CFZ in combination or not with 10 μM AGI-6780. 
Cell viability was measured by TMRM staining-flow cytometry 72 hours post-treatment. 
Data are the means ± s.d. of four independent experiments. (D) Eight MM cell lines and 
the K-562 cell line were treated with CFZ (1.67 nM CFZ for KMS-18; 2.5 nM for RPMI-
8226, KMS-27, SK-MM-1, and CMA-03; 5 nM for KMM-1, U266, and NCI-H929 cell lines) 
in combination or not with 5 μM AGI-6780 (2.5 μM for RPMI-8226). Treatment was 
performed every 48h for AGI-6780, only at day 0 for CFZ. Cell viability was measured by 
TMRM staining-flow cytometry 8 days post-treatment. Data are the means ± s.d. of three 
independent experiments (*P<.05; **P<.01; ***P<.001; #P≥.05). (E) Western blot of KMM-
1 and NCI-H929 cells, untreated (UT), treated with DMSO, AGI-6780 (KMM-1: 5 μM; NCI-
H929: 10 μM), CFZ (KMM-1: 5 nM; NCI-H929: 2.5 nM), or the combination of the two 
drugs. Cell lysates were immunoblotted using the indicated antibodies 24 hours post-
treatment. Vinculin protein expression was included for protein loading normalization. (F-
G) Cell viability of the experiment described above was measured by TMRM staining-flow 
cytometry 24 and 72 hours post-treatment (hpt), respectively. 
 
Figure 3. IDH2 inhibition increases sensitivity to CFZ in mantle cell lymphoma and 
Burkitt’s lymphoma cells. (A) JeKo-1, (B) SP-49, (C) Mino, (D) Granta-519, (E) HS-
Sultan, and (F) Raji cells were left untreated (UT), treated with DMSO, CFZ, AGI-6780, or 
the combination of the two drugs. JeKo-1 cells were treated at time 0, 48h, and 96h with 
both drugs. SP-49 cells were treated at time 0 and 48h with both drugs and at 96h with 
AGI-6780. Mino cells were treated with both drugs at time 0 and with AGI-6780 at 48h and 
96h. Granta-519 cells were treated at time 0h and 48h with both drugs and every 48h with 
AGI-6780. HS-Sultan cells were treated at time 0 with both drugs and every 48h with AGI-
6780. Raji cells were treated at time 0 and 48h with both drugs and every 48h with AGI-
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6780. Cell viability was measured by TMRM staining-flow cytometry at the indicated time 
points. Data are the means ± s.d. of four independent experiments (*P<.05; **P<.01; 
***P<.001). 
 
Figure 4. Combinatorial treatment with CFZ and AGI-6780 causes a reduction in 
IDH2 activity and mATP levels. (A) KMS-27 and (B) KMM-1PIR cells untreated (UT), 
treated with DMSO, CFZ (2.5 nM and 5 nM, respectively), AGI-6780 (5 µM), or the 
combination of the two drugs were analyzed for IDH2 activity 6 hours post-treatment. (C) 
KMS-27 and (D) KMM-1PIR cells treated as described above were analyzed for 
tricarboxylic acid (TCA) cycle activity 6 hours post-treatment. Data are the means ± s.d. of 
four independent experiments. (E) KMS-27 cells treated as described above were 
analyzed for electron transport chain (ETC) complexes I to III 7 hours post-treatment. (F) 
KMS-27 cells treated as described above were analyzed for mitochondrial ATP (mATP) 
production 7 hours post-treatment. Data are the means ± s.d. of three independent 
experiments (*P<.05; **P<.01; ***P<.001).  
 
Figure 5. Combinatorial treatment with CFZ and AGI-6780 acts through the inhibition 
of the NAMPT/SIRT/IDH2 pathway. (A) Schematic representation of the 
NAMPT/SIRT3/IDH2 pathway and inhibitors. (B) KMS-27 cells treated with DMSO, AGI-
6780 (5 µM), CFZ (3 nM), or the combination of the two drugs were analyzed for NF-κB 
activity 6 hours post-treatment. NF-κB activity was detected in total extracts measuring the 
DNA-binding capability of NF-κB on its target sequence (see Methods). Data represent the 
percentage of NF-κB binding activity normalized versus DMSO samples and are the 
means ± s.d. of three independent experiments. (C) KMS-27 cells untreated (UT), treated 
with DMSO, CFZ (2.5 nM), AGI-6780 (5 µM), or the combination of the two drugs were 
analyzed for NAMPT mRNA expression levels 24hours post-treatment. Data are the 
means ± s.d. of three independent experiments. (D-E) KMS-27 cells were left untreated 
(UT), treated with DMSO or FK866 (10 nM), for 48 hours, vehicle or CFZ (2.5 nM) were 
added for additional 48 hours. Cells were analyzed for (D) IDH2 activity 6 hours post-
treatment with CFZ and for (E) cell viability by TMRM staining-flow cytometry 6 and 48 
hours post-treatment with CFZ (hpt). Data are the means ± s.d. of three independent 
experiments. (F-G) KMS-27 cells untreated (UT), treated with DMSO, 1.25 nM CFZ, 10 µM 
AGK7, or the combination of the two drugs were analyzed for (F) IDH2 activity 6 hours 
post-treatment and for (G) cell viability measured by TMRM staining-flow cytometry 6 and 
48 hours post-treatment (hpt). Data are the means ± s.d. of three independent 
experiments (*P<.05; **P<.01; ***P<.001). 
 
Figure 6. Targeting IDH2 and proteasome activities triggers synergistic inhibition of 
human MM cells growth ex-vivo and in vivo with low toxicity to normal human cells. 
(A) Buffy coats derived from bone marrow aspirates of MM patients were treated with CFZ 
(2.5 nM) in combination or not with AGI-6780 (5 μM). Cell viability was estimated by FACS 
measuring Annexin V- and CD138+ cells 96 hours post-treatment. Histograms represent 
the percentage of viable cells normalized versus DMSO samples. Data are the means ± 
s.e.m. of nine independent MM patients. (B) Peripheral blood mononuclear cells (PBMCs) 
and KMS-27 were treated with DMSO, CFZ (1.25, 2.5, 5, 10 nM), AGI-6780 (5 μM), or the 
combination of the two drugs. PBMCs were derived from 4 healthy donors. Cell viability 
was measured by TMRM staining-flow cytometry 48h post-treatment. Data are the means 
± s.d. (*P<.05; **P<.01; ***P<.001). (C) KMS-27-TK cells (expressing DsRed fluorescent 
protein) were co-coltured with HS-5 bone marrow/stroma cell line and treated with CFZ, 
AGI-6780, or the combination. Percentage of live DsRed+ cells was measured overtime. 
Data are the means ± s.d. of three independent experiments (CFZ vs CFZ+AGI-6780 
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**P<.01). (D) Growth patterns of KMS-27-TK-IDH2-A4 cells injected subcutaneously into 
the flanks of NOD/SCID/IL2Rγ−/− (NSG) mice. Tumor masses of 0.5 cm diameter mice 
were randomized for treatment with vehicle (n = 6), 4 mg/kg CFZ (n = 8), 0.1 mg/mL 
DOXY (n = 10), or the combination of both compounds (n = 10) over 3 weeks. 
Administration of either agent had a substantial effect on tumor growth, as compared to 
control mice (P<.0001). Combination of IDH2 silencing with CFZ further reduced tumor 
growth in relation to single treatments (CFZ vs CFZ/DOXY P=.0244; DOXY vs CFZ/DOXY 
P=.0238). Each data point represents the average tumor volume (mean ± standard error of 
the mean) for the indicated treatment condition. The timeline shows the schedule of 
treatment followed for in vivo treatments. (E) Kaplan–Meier survival plot showing survival 
for mice treated with vehicle (n = 6), 4 mg/kg CFZ (n = 6), 0.1 mg/mL DOXY (n = 8), or 
their combination (n = 6). CFZ plus DOXY-treated mice show significantly increased 
survival (49 days) in comparison with vehicle-treated mice (26 days; P<.0001), CFZ alone 
(35 days; P=.0007), and DOXY alone (38 days; P=.0472).  
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